Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice

Neuroscience

Volumn 236, Issue , 2013, Pages 66-76

  Li, L ^a,b   Zhou, F M ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Basal ganglia; Dopamine D1 receptor; Dyskinesia; L 3,4 dihydroxyphenylalanine (l dopa); Medium spiny neuron; Parkinson's disease

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BENSERAZIDE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; ROPINIROLE; TRANSCRIPTION FACTOR PITX3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MOVEMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG DOSE COMPARISON; DYSKINESIA; GENE MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; IMMUNOHISTOCHEMISTRY; LEVODOPA; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D1;

EID: 84874357812     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.12.065     Document Type: Article

References (64)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949-956.
3. Bateup H.S., Santini E., Shen W., Birnbaum S., Valjent E., Surmeier D.J., Fisone G., Nestler E.J., Greengard P. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010, 107:14845-14850.
4. Beeler J.A., Cao Z.F., Kheirbek M.A., Zhuang X. Loss of cocaine locomotor response in Pitx3-deficient mice lacking a nigrostriatal pathway. Neuropsychopharmacology 2009, 34:1149-1161.
5. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
6. Berthet P., Hellgren-Kotaleski J., Lansner A. Action selection performance of a reconfigurable basal ganglia inspired model with Hebbian-Bayesian Go-NoGo connectivity. Front Behav Neurosci. 2012, 6:65.
7. Cenci M.A. Molecular mechanisms of l-dopa-induced dyskinesia. Handbook of Basal Ganglia Structure and Function 2010, 625-640. Academic Press, San Diego. H. Steiner, K.Y. Tseng (Eds.).
8. Cheng H.C., Ulane C.M., Burke R.E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010, 67:715-725.
9. Chevalier G., Deniau J.M. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 1990, 13:277-280.
10. Corvol J.C., Muriel M.P., Valjent E., Féger J., Hanoun N., Girault J.A., Hirsch E.C., Hervé D. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 2004, 24:7007-7014.
11. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism - chronic treatment with l-dopa. N Engl J Med 1969, 280:337-345.
12. Darmopil S., Martín A.B., De Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009, 66:603-613.
13. Delong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990, 13:281-2855.
14. Ding Y., Restrepo J., Won L., Hwang D.Y., Kim K.S., Kang U.J. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 2007, 27:11-23.
15. Ding Y., Won L., Britt J.P., Lim S.A., McGehee D.S., Kang U.J. Enhanced striatal cholinergic neuronal activity mediates l-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 2011, 108:840-845.
16. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov Disord 2007, 22:1379-1389.
17. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?. Ann Neurol 2008, 64(Suppl 2):S56-S64.
18. Fahn S., Przedborki S. Parkinsonism. Merritt's Neurology 2005, 828-846. Lippincott Williams & Wilkins, New York. L.P. Rowland (Ed.).
19. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004, 24:9434-9440.
20. Fox S.H., Lang A.E. Levodopa-related motor complications - phenomenology. Mov Disord. 2008, 23(Suppl 3):S509-514.
21. Gottwald M.D., Aminoff M.J. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011, 69:919-927.
22. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., Gurevich E.V., Gross C.E., Bezard E. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 2005, 22:283-287.
23. Hikosaka O., Takikawa Y., Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 2000, 80:953-978.
24. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., Rudolf J., Herholz K., Heiss W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity. Arch Neurol 2005, 62:378-382.
25. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia - normal and in Parkinson's disease. J Chem Neuroanat 2001, 22:3-12.
26. Hung S.W., Adeli G.M., Arenovich T., Fox S.H., Lang A.E. Patient perception of dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2010, 81:1112-1115.
27. Huot P., Fox S.H., Newman-Tancredi A., Brotchie J.M. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?. J Pharmacol Exp Ther 2011, 339:2-8.
28. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.F., Kim K.S. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 2005, 25:2132-2137.
29. Iravani M.M., Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 2011, 118:1661-1690.
30. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003, 16(Suppl. 1):S3-7.
31. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-677.
32. Katzenschlager R., Head J., Schrag A., Ben-Shlomo Y., Evans A., Lees A.J. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008, 71:474-480. Parkinson's Disease Research Group of the United Kingdom.
33. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
34. Kuoppamaki M., Al-Barghouthy G., Jackson M.J., Smith L.A., Quinn N., Jenner P. l-Dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J Neural Transm 2007, 114:1147-1153.
35. Langston J.W. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 1985, 36:201-206.
36. Lee C.S., Schulzer M., de la Fuente-Fernández R., Mak E., Kuramoto L., Sossi V., Ruth T.J., Calne D.B., Stoessl A.J. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 2004, 61:1920-1925.
37. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A 1993, 90:8861-8865.
38. Lewitt P.A. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2009, 359:2468-2476.
39. Lewitt P.A. Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?. Neurology 2010, 74:1169-1170.
40. Lundblad M., Usiello A., Carta M., Håkansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-dopa-induced dyskinesia. Exp Neurol 2005, 194:66-75.
41. Moretti R., Torre P., Antonello R.M., Esposito F., Bellini G. The on-freezing phenomenon: cognitive and behavioral aspects. Parkinsons Dis 2011, 2011:746303.
42. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
43. Nadjar A., Gerfen C.R., Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?. Prog Neurobiol 2009, 87:1-9.
44. Nunes I., Tovmasian L.T., Silva R.M., Burke R.E., Goff S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 2003, 100:4245-4250.
45. Nutt J.G. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008, 23(Suppl. 3):S580-584.
46. Nutt J.G., Chung K.A., Holford N.H. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010, 74:1191-1197.
47. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72(21 Suppl 4):S1-136.
48. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2007, 323:277-284.
49. Santini E., Heiman M., Greengard P., Valjent E., Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents l-DOPA-induced dyskinesia. Sci Signal 2009, 2(80):ra36.
50. Schapira A.H., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 2006, 59:559-562.
51. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996, 50:275-331.
52. Smidt M.P., Smits S.M., Bouwmeester H., Hamers F.P., Van Der Linden A.J., Hellemons A.J., Graw J., Burbach J.P. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 2004, 131:1145-1155.
53. Smith Y., Wichmann T., Factor S.A., DeLong M.R. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 2012, 37:213-246.
54. Smits S.M., Burbach J.P., Smidt M.P. Developmental origin and fate of meso-diencephalic dopamine neurons. Prog Neurobiol 2006, 78:1-16.
55. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 2005, 3:e271.
56. Standaert D.G., Young A.B. Treatment of central nervous system degenerative disorders. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2006, 527-545. McGraw-Hill, New York. L. Brunton, J. Lazo, K. Parker (Eds.).
57. Stockwell K.A., Virley D.J., Perren M., Iravani M.M., Jackson M.J., Rose S., Jenner P. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol 2008, 211:172-179.
58. Taylor T.N., Greene J.G., Miller G.W. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res 2010, 211:1-10.
59. van den Munckhof P., Luk K.C., Ste-Marie L., Montgomery J., Blanchet P.J., Sadikot A.F., Drouin J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 2003, 130:2535-2542.
60. Voorn P., Vanderschuren L.J., Groenewegen H.J., Robbins T.W., Pennartz C.M. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 2004, 27:468-474.
61. Yung K.K., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., Levey A.I. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995, 65:709-730.
62. Zhou F.-M., Liang Y., Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001, 4:1224-1229.
63. Zhou F.-M., Liang Y., Salas R., Zhang L., De Biasi M., Dani J.A. Co-release of dopamine and serotonin from striatal dopamine terminals. Neuron 2005, 46:65-74.
64. Zhou F.W., Jin Y., Matta S.G., Xu M., Zhou F.-M. An ultra-short dopamine pathway regulates basal ganglia output neurons. J Neurosci 2009, 29:10424-11035.